Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03821246 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
A Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by David Oh.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 2
- Study locations
NCT03821246 is a Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma that is actively recruiting participants, run by David Oh. The registered enrollment target is 68 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03821246, a Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, is actively recruiting participants, sponsored by David Oh.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgens can cause the growth of prostate cancer cells. IL-6 is expressed by prostate cancer and within the tumor microenvironment and shown to enhance prostate cancer and disease progression. Treatment with an anti-IL-6 antibody such as tocilizumab may inhibit cancer progression. Giving atezolizumab in combination with etrumadenant or tocilizumab may work better in treating prostate cancer.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Tocilizumab
- DRUG Etrumadenant
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Missouri
- Alvin J. Siteman Cancer Center at Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03821246
The ClinicalTrials.gov registry entry for NCT03821246 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (89% lower). The listed sponsor is David Oh, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03821246 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Missouri.
Frequently Asked Questions
What is clinical trial NCT03821246 about?
NCT03821246 is a clinical study titled "Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy". This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the c...
What is the current status of trial NCT03821246?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2019-10-30. Estimated completion is 2026-04-30.
What conditions does trial NCT03821246 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Cancer.
What interventions are being tested in trial NCT03821246?
The interventions under investigation include: Atezolizumab (DRUG), Tocilizumab (DRUG), Etrumadenant (DRUG).
Who is sponsoring clinical trial NCT03821246?
This trial is sponsored by David Oh, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03821246 being conducted?
This trial has 2 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.